Hong Kong Other Utilities Stock News

WuXi Biologics (Cayman) (SEHK:2269) recently obtained ISO 13485:2016 certification for its medical device quality management system with zero non conformities, an event that draws attention to how quality and compliance feed into its equity story. See our latest analysis for WuXi Biologics (Cayman). The ISO 13485:2016 win comes as the share price trades at HK$37.18, with a 1 month share price return of 6.41% and a year to date share price return of 14.26%. Over a longer horizon, the 1 year...

MiniMax Group overview and recent trading context MiniMax Group (SEHK:100) has drawn fresh attention after recent volatility, with a 6.3% gain over the past day contrasting with weaker moves over the past week and month. See our latest analysis for MiniMax Group. The recent 6.3% one day share price return comes after a weaker patch, with the 7 day and 30 day share price returns of 9.8% and 12.8% sitting against a very strong 90 day share price return of 105.6% and year to date share price...

Latest FY 2025 earnings snapshot NetEase (SEHK:9999) has just wrapped up FY 2025 with fourth quarter revenue of C¥27.5b and basic EPS of C¥1.96, rounding out a trailing twelve month revenue base of C¥112.6b and EPS of C¥10.59. Over the last six reported quarters, revenue has ranged from C¥26.2b in Q3 2024 to C¥28.8b in Q1 2025, while quarterly EPS has moved between C¥2.04 and C¥3.25. This gives investors a clear view of how the earnings line has tracked the top line. With trailing net profit...

NetEase Cloud Music (SEHK:9899) has posted its FY 2025 results with second half revenue of C¥3,932.3 million and basic EPS of C¥4.08, while investors also have a full year view from trailing 12 month revenue of C¥7,759.5 million and EPS of C¥13.02. The company has seen revenue move from C¥3,879.7 million and EPS of C¥3.60 in the second half of FY 2024 to C¥3,932.3 million and EPS of C¥4.08 in the latest half, with the trailing 12 month EPS rising from C¥7.48 to C¥13.02 alongside a net profit...

Share repurchase launch puts Horizon Robotics in focus Horizon Robotics (SEHK:9660) has begun repurchasing shares under a shareholder mandated program that authorizes buybacks of up to 10% of its issued share capital, drawing fresh attention to the stock. See our latest analysis for Horizon Robotics. At a latest share price of HK$7.17, Horizon Robotics has had a 1 day share price return of 0.84% and a 90 day share price decline of 23.56%, while its 1 year total shareholder return of 29.89%...

If you are wondering whether Agricultural Bank of China shares offer good value right now, the key is to separate headline performance from what the current price actually implies. The stock last closed at HK$6.00, with returns of 4.9% over 7 days, 13.9% over 30 days, 2.9% year to date, 40.4% over 1 year, 148.0% over 3 years and 184.9% over 5 years, which is likely to have caught the attention of many investors. These returns have put Agricultural Bank of China on the radar of market...

Cathay Pacific Airways stock triggered overview Cathay Pacific Airways (SEHK:293) has recently drawn investor attention after posting annual revenue of HK$116,766.0 million and net income of HK$10,828.0 million. This has put fresh focus on how its share performance lines up with these fundamentals. See our latest analysis for Cathay Pacific Airways. The share price has been under pressure in recent months, with a 30 day share price return of 5.52% and a year to date share price return of...

Hansoh Pharmaceutical Group (SEHK:3692) has secured NMPA approval for XINYUE’s third indication, targeting adult patients with generalized myasthenia gravis, and expanding its rare autoimmune disease footprint supported by positive Phase III MINT trial data. See our latest analysis for Hansoh Pharmaceutical Group. The XINYUE approval lands at a time when the share price has climbed to HK$39.4, with a 30 day share price return of 21.6% and a 1 year total shareholder return of 82.34%. This...

Beijing Yunji Technology Co., Ltd. ( HKG:2670 ) is possibly approaching a major achievement in its business, so we...

The market for Swire Pacific Limited's ( HKG:19 ) shares didn't move much after it posted weak earnings recently. We...

Amid improving global market sentiment following a U.S.-Iran ceasefire agreement, Asian markets have shown resilience and potential for growth. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Lenovo Group (SEHK:992) has formed an alliance with Konecta to develop AI powered digital workplace solutions. The partnership focuses on an integrated model for IT outsourcing and digital workplace services using AI platforms. The collaboration is set to affect more than 100,000 employees across a global footprint. The move aligns with Lenovo’s broader shift toward services led and outcome based business models. For Lenovo Group, best known for PCs, infrastructure and devices, the alliance...

Global markets have recently experienced a boost in investor sentiment, driven by a ceasefire agreement between the U.S. and Iran, which has helped ease geopolitical tensions and lower oil prices. As major indices like the Nasdaq Composite see significant gains, investors are increasingly looking for opportunities that balance risk with potential rewards. Though "penny stocks" might seem like an outdated term, they continue to offer intriguing prospects for growth. These stocks often...

As global markets respond positively to a U.S.-Iran ceasefire, investor sentiment has improved, leading to gains across major indices. In this context, penny stocks—often representing smaller or newer companies—can still offer intriguing opportunities for growth when backed by solid financial health. Despite being considered a niche investment area today, these stocks can provide value and potential upside for those looking beyond larger firms.

Aluminum Corporation of China (SEHK:2600) issued first quarter 2026 earnings guidance, flagging net profit of CN¥5,302 million to CN¥5,585 million and basic EPS of CN¥0.310 to CN¥0.326, both implying 50% to 58% year-on-year growth. See our latest analysis for Aluminum Corporation of China. The earnings guidance comes after a sharp re-rating, with the 1-year total shareholder return of about 3x and a more muted share price return of 0.32% year to date at HK$12.68. Recent 7-day strength...

Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in China for LY03020, a dual TAAR1 and 5-HT2CR agonist targeting schizophrenia. See our latest analysis for Luye Pharma Group. The LY03020 trial update comes as Luye Pharma Group’s share price sits at HK$2.89, with a 30-day share price return of 18.93% contrasting with a 90-day share price decline of 3.99%. The 1-year total shareholder return of 55.38% stands against a...

Why Xiaomi’s stock is drawing fresh attention Xiaomi (SEHK:1810) is back on investors’ radar after recent trading left the share price lower over the past month and the past 3 months, prompting closer scrutiny of its current valuation and business mix. See our latest analysis for Xiaomi. At the latest share price of HK$30.88, Xiaomi’s recent 30 day share price return of 7.32% and year to date share price return of 23.34% contrast with a 3 year total shareholder return of 148.23%. This...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Renewed agreements with Yili Group set the context China Youran Dairy Group (SEHK:9858) has renewed long term supply and financial agreements with controlling shareholder Yili Group. These agreements lock in their commercial relationship from 2027 to 2029 and formalize ongoing raw milk and dairy product transactions. See our latest analysis for China Youran Dairy Group. The renewed Yili contracts arrive after a weaker patch for the shares, with a 30 day share price return of 5.58% and a 90...

Dongfang Electric (SEHK:1072) has drawn fresh attention after reporting full year 2025 results alongside a declared final ordinary dividend of RMB 5.3 per 10 shares, providing both earnings and income updates for shareholders. See our latest analysis for Dongfang Electric. The full year results and higher dividend have arrived against a strong backdrop, with a 90 day share price return of 60.83% and a very large 1 year total shareholder return that far outpaces the short term moves. If...

Central New Energy Holding Group (SEHK:1735) reported full year 2025 results, with sales of HK$11,016.85 million, net income of HK$34.24 million, and earnings per share of HK$0.0081 from continuing operations. See our latest analysis for Central New Energy Holding Group. The earnings release comes after a steady run in the shares, with a 9.55% 1 month share price return and 12.30% 3 month share price return. However, the 1 year total shareholder return is still down 6.58% while the 5 year...

Genscript Biotech (SEHK:1548) is back in focus after announcing a multi year collaboration with Mimulus Corp to industrialize DNA based data storage, targeting scalable infrastructure and substantial cost efficiencies by 2030. See our latest analysis for Genscript Biotech. The collaboration headlines come as Genscript Biotech's share price, now at HK$12.62, shows mixed momentum, with a 13.8% 1 month share price return but a 12.42% decline over 3 months. The 1 year total shareholder return...

Zhejiang Expressway Co., Ltd. recently reported its full-year 2025 results, with sales rising to CNY 19.76 billion while net income eased slightly to CNY 5.32 billion, and recommended a higher dividend of CNY 0.395 per share, all subject to approval at the 2025 annual shareholders’ meeting. The combination of revenue growth, a modest earnings dip and a proposed dividend increase highlights management’s emphasis on returning cash to shareholders while operating profitability remains under...

Akeso (SEHK:9926) has come into focus after presenting new lung cancer data at the 2026 European Lung Cancer Congress. The company updated investors on cadonilimab and ivonescimab across difficult non small cell lung cancer settings. See our latest analysis for Akeso. Following the ELCC updates, Akeso's HK$137.8 share price sits on the back of a 25.05% 1 month share price return and 21.62% year to date share price return. The 1 year total shareholder return of 58.48% and 3 year total...